Duke logo

AbbVie M14-064 for Metastatic Colorectal Cancer - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find if the study drug called ABT-165 given in combination with
the standard of care treatment, FOLFIRI, will work better than an approved standard treatment
combination for metastatic colorectal cancer.

What is the Condition Being Studied?

Colorectal Cancer

Who Can Participate in the Study?

Adults who:
- Have colorectal cancer
- Have received prior therapy that included a fluoropyrimidine, oxaliplatin, and bevacizumab

Age Group
Adults

What is Involved?

If you choose to join this study you will:
- Be randomized (like the flip of a coin) to either get:
-- The study drug ABT-165 plus FOLFIRI OR Bevacizumab plus FOLFIRI through your vein
--- Infusions will be given on Day 1 of each 14-day cycle
- Have tests, exams, and procedures that are part of your standard care and for study purposes

Study Details

Full Title
Phase 2 Study Comparing Efficacy and Safety of ABT-165 plus FOLFIRI vs Bevacizumab plus FOLFIRI in Metastatic Colorectal Cancer Previously Treated with Fluoropyrimidine, Oxaliplatin and Bevacizumab
Principal Investigator
Medical Oncologist
Protocol Number
IRB:PRO00091044
NCT:NCT03368859
Phase
Phase II
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
studyrecruitment@duke.edu
or
919-681-5698